5月15日，医疗器械生产商沛嘉医疗在联交所主板成功上市，共募集约23.43亿港元资金。美迈斯律师事务所、竞天公诚律师事务所、上海上正恒泰律师事务所担任发行人律师，史密夫斐尔律师事务所、通商律师事务所则担任联席保荐人及包销商法律顾问。
沛嘉医疗是第17家根据联交所18A规则上市的生物科技企业，其达成冻资额超2800亿港元，成为了今年截至目前的港股“冻资王”。
成立于2012年，沛嘉医疗总部设于苏州，主要生产经导管瓣膜治疗医疗器械及神经介入医疗器械。其产品主要为中国患者及医疗服务提供者所设计。
Campbells就开曼群岛法律提供意见；广东君龙律师事务所则就中国知识产权法律提供意见。
摩根士丹利和华泰国际担任本次发行联席保荐人。
上正恒泰团队本项目牵头律师为合伙人刘阳芳；美迈斯团队牵头律师为合伙人耿科和朱柯；史密夫斐尔团队牵头律师为合伙人艾迈修、Siddhartha Sivaramakrishnan和谢守德。
Jingtian & Gongcheng, Hengtai, C&F, OMM, HSF on Peijia Medical’s $302 mln HK IPO
O’Melveny & Myers, Campbells Law Firm, Jingtian & Gongcheng, Hengtai Law Offices, and Guangdong Junlong Law Firm have advised on Peijia Medical’s HK$2.34 billion ($302 million) IPO on the Hong Kong Stock Exchange. Herbert Smith Freehills and Commerce & Finance Law Offices represented the underwriters.
Peijia Medical is a medical devices provider of heart and neurovascular diseases equipment specifically offering services for Chinese patients and healthcare providers.
The IPO was over-subscribed by more than 1,100 times attracting 14 cornerstone investors that subscribed to ($151 million) worth of shares.
The Herbert Smith team was led by partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie.
Morgan Stanley and Huatai Financial acted as joint sponsors in the deal. Campbells and Guangdong Junlong Law Firm acted as offshore counsel and intellectual property counsel of the issuer, respectively.
The Hengtai team was led by partner Liu Yangfang; the OMM team was led by partners Geng Ke, Zhu Ke; and the HSF team was led by partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
